Research Article
Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients
Figure 1
Tornado diagram representing the univariate sensitivity analysis for L-sarcoma, numbers abbreviated to thousands. All variables other than survival were increased (light-shaded bars) or decreased (dark-shaded bars) by 20%. For progression-free survival and overall survival, the 95% confidence interval (95% CI) of the survival difference between trabectedin and ifosfamide was used (low end: light-shaded bars; high end: dark-shaded bars). Note that the bar for the low end of the difference in OS does not stop and no number is given, as ifosfamide dominated trabectedin at that point, with a negative ICER. OS: overall survival; PFS: progression-free survival.